Clinical Review

Effects of Exenatide on Diabetes Management and Weight Loss in a VA Population

Author and Disclosure Information

One of the relatively new class of incretin mimetics, exenatide has not been as well studied as some other antidiabetic medications. This study aimed to evaluate how well the drug is working for veterans with type 2 diabetes and how closely VA providers are adhering to established guidelines for use.


 

Recommended Reading

Olmesartan Lowers Microalbuminuria in Type 2
Type 2 Diabetes ICYMI
TESST Predicts Cardiac Risk in Elderly Diabetics
Type 2 Diabetes ICYMI
Asians at Increased Risk for Gestational Diabetes
Type 2 Diabetes ICYMI
Societies Team Up for Diabetic Limb Salvage
Type 2 Diabetes ICYMI
Height Is a Risk Factor for Amputations
Type 2 Diabetes ICYMI
Heart Failure Increases New-Onset Diabetes Risk
Type 2 Diabetes ICYMI
Noninvasive CIMT Scan Predicts Poor Myocardial Perfusion
Type 2 Diabetes ICYMI
ADVANCE Yields More Data On Heart Risk in Diabetes
Type 2 Diabetes ICYMI
Comparing Antithrombotic Regimens for Diabetic Patients Undergoing PCI
Type 2 Diabetes ICYMI
The Role of Incretin-Based Therapies in Treating Patients with Type 2 Diabetes Mellitus
Type 2 Diabetes ICYMI